April – June 2021 Net revenue for the period was SEK 117.6 million (101.8) EBITDA for the period was SEK 15.8 million (15.1) EBITA for the period was SEK 13.3 million (13.1) Profit/loss for the period was SEK 0.1 million (8.3) Basic earnings per share for the period amounted to SEK 0.00 (0.07) Orders received…
Read moreADDvise Group is an expanding group that offers total solutions in the form of products and services to healthcare and research facilities through its subsidiaries within the business units Lab and Healthcare.
Expanding and developing ADDvise and our subsidiaries today feels more important than ever. We strive to extend, improve, and save people’s lives by developing and providing products and services for healthcare and research segments.
April – June 2021 Net revenue for the period was SEK 117.6 million (101.8) EBITDA for the period was SEK 15.8 million (15.1) EBITA for the period was SEK 13.3 million (13.1) Profit/loss for the period was SEK 0.1 million (8.3) Basic earnings per share for the period amounted to SEK 0.00 (0.07) Orders received…
Read moreADDvise Group AB (publ) issued on 21 May 2021 a senior secured bond loan of SEK 250,000,000 within a total framework amount of SEK 500,000,000 on the Swedish bond market. The bonds carry a floating rate interest of STIBOR 3m + 7.25 per cent per annum and matures 21 May 2024. ADDvise has applied for…
Read moreADDvise Group AB (publ) (”ADDvise”) has today completed the acquisition of all shares in MRC Systems FZE (”MRC”). The signing of the share purchase agreement has been communicated to the market via a press release on 16 February 2021. The total purchase price amounts to USD 8.00 million, of which USD 4.50 million has been…
Read moreWe refer to the outstanding up to SEK 240,000,000 senior secured callable bonds issued by ADDvise Group AB (publ) (the "Company") with ISIN: SE0010298166 (the "Bonds") and to the terms and conditions of the Bonds (the "Terms and Conditions"). Reference is further made to a call notice dated 21 May 2021, in which the Company…
Read more
ADDvise Interim report Q1 2021 with comments from CEO Rikard Akhtarzand. Entered the first quarter with strong sales; SEK 87.7 million (83.7). EBITDA amounted to SEK 8.9 million (5.4), with an EBITDA margin of 10.1 percent (6.4). Rolling 12 sales came in at SEK 362.5 million with an EBITDA of SEK 49.7 million. Improvements was driven by positive development in our core areas of patient positioning, X-ray, emergency care and equipment for research laboratories.
For more presentations please visit our YouTube channel.
Together we become stronger describes ADDvise leadership strategy. They work guiding and supportive. We have gained access to support functions we did not have in the business before. This has enabled us to easily develop the business and streamline many of our processes and working methods, Jonny Knekthage, CEO Tillquist.
ADDvise delivers equipment and services to healthcare and research units worldwide. The global market for medical technology is growing and is expected to continue to grow in the upcoming years.
ADDvise Group’s two business units Lab and Healthcare are part of the organizational facilitation of the stated acquisition strategy. Together, the business areas create a complete offer for our customers.
Here you will find financial information so that you as a shareholder, analyst or investor can be up to date. Financial reports, press releases and other company information.
Subscribe to our press releases and receive the information directly in the email.
